MX2012007671A - Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea. - Google Patents

Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea.

Info

Publication number
MX2012007671A
MX2012007671A MX2012007671A MX2012007671A MX2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A
Authority
MX
Mexico
Prior art keywords
corneal endothelial
endothelial cells
compound
therapeutic agent
agent
Prior art date
Application number
MX2012007671A
Other languages
English (en)
Inventor
Yuji Sakamoto
Tetsuo Kida
Hiroaki Takahashi
Takeshi Tarui
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2012007671A publication Critical patent/MX2012007671A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención presente se propone proporcionar medios para tratar conveniente y efectivamente enfermedades en donde las células endoteliales de la córnea deficientes en capacidad proliferativa in vivo están dañadas; la invención presente proporciona un agente terapéutico para la disfunción endotelial de la córnea que contiene (R)-(+)-N-(1H-pirrolo[2,3- b]piridin-4-iI)-4-(1-aminoetil )benzamida <Y-39983> o una sal farmacológicamente aceptable del mismo (compuesto (la)) como ingrediente activo, un agente para promover la adhesión de células endoteliales de la córnea, que contiene el compuesto (la), un medio de cultivo para células endoteliales de la córnea, que contiene al agente para promover la adhesión, un implante para la queratoplastía endotelial de la córnea, que contiene células endoteliales de la córnea, un andamio y el compuesto (la), y un método de producción de una preparación endotelial de la córnea, incluyendo un paso de cultivar células endoteliales de la córnea utilizando el medio de cultivo.
MX2012007671A 2009-12-29 2010-12-28 Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea. MX2012007671A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009299180 2009-12-29
PCT/JP2010/071424 WO2011080984A1 (en) 2009-12-29 2010-11-24 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
PCT/JP2010/073904 WO2011081221A1 (en) 2009-12-29 2010-12-28 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction

Publications (1)

Publication Number Publication Date
MX2012007671A true MX2012007671A (es) 2012-08-23

Family

ID=43598277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007671A MX2012007671A (es) 2009-12-29 2010-12-28 Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea.

Country Status (10)

Country Link
US (1) US20120288482A1 (es)
EP (1) EP2519237A1 (es)
JP (2) JP5750444B2 (es)
KR (1) KR20120099147A (es)
CN (1) CN102770136A (es)
BR (1) BR112012016128A8 (es)
CA (1) CA2785851A1 (es)
MX (1) MX2012007671A (es)
RU (1) RU2563141C2 (es)
WO (2) WO2011080984A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58526B1 (sr) * 2011-12-06 2019-04-30 Astellas Inst For Regenerative Medicine Postupak usmerene diferencijacije koja proizvodi kornealne endotelijalne ćelije
US11624053B2 (en) 2013-11-27 2023-04-11 Kyoto Prefectural Public University Corporation Application of laminin to corneal endothelial cell culture
US10959997B2 (en) 2013-12-27 2021-03-30 Kyoto Prefectural Public University Corporation Combined agent for cell therapy of corneal endothelial cell
US10034885B2 (en) 2014-09-24 2018-07-31 Kowa Company, Ltd. Corneal thickness modulating agent
CA2965770C (en) 2014-10-31 2024-02-13 Kyoto Prefectural Public University Corporation Treatment of cornea using laminin
EP3213761B1 (en) 2014-10-31 2021-05-19 Kyoto Prefectural Public University Corporation Novel treatment of retina using laminin
US20190083543A1 (en) * 2016-02-15 2019-03-21 Kyoto Prefectural Public University Corporation Human functional corneal endothelial cell and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
US7109208B2 (en) 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
JP2004024852A (ja) 2002-04-30 2004-01-29 Amniotec:Kk 角膜内皮様シート、及びその作製方法
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
EP1752456B1 (en) * 2004-06-03 2015-08-26 Senju Pharmaceutical Co., Ltd. Corneal perception recovery drug containing amide compound
EP1829876A4 (en) * 2004-11-26 2009-04-01 Asahi Kasei Pharma Corp NITROGENIC TRICYCLIC COMPOUND
JP4766653B2 (ja) * 2005-01-28 2011-09-07 株式会社林原生物化学研究所 眼科用医薬組成物
JPWO2006095844A1 (ja) * 2005-03-10 2008-08-21 田辺三菱製薬株式会社 医薬製剤
US10052411B2 (en) * 2006-01-19 2018-08-21 Senju Pharmaceutical Co., Ltd. Methods of treating corneal related diseases by corneal endothelial preparation which enables cells to grow in vivo
US20090247552A1 (en) * 2006-07-31 2009-10-01 Shirou Sawa Aqueous liquid preparation containing amide compound
KR20240045364A (ko) 2007-08-29 2024-04-05 센주 세이야꾸 가부시키가이샤 각막 내피 세포 접착 촉진제
JP5251632B2 (ja) 2008-05-13 2013-07-31 新日鐵住金株式会社 耐遅れ破壊特性に優れた高強度鋼材、高強度ボルト及びその製造方法
JP2010071424A (ja) 2008-09-19 2010-04-02 Toyota Motor Corp 変速機の制御装置

Also Published As

Publication number Publication date
KR20120099147A (ko) 2012-09-06
JP2013515676A (ja) 2013-05-09
JP2015155460A (ja) 2015-08-27
BR112012016128A8 (pt) 2017-12-05
JP5750444B2 (ja) 2015-07-22
CN102770136A (zh) 2012-11-07
US20120288482A1 (en) 2012-11-15
WO2011080984A1 (en) 2011-07-07
BR112012016128A2 (pt) 2016-05-31
RU2563141C2 (ru) 2015-09-20
CA2785851A1 (en) 2011-07-07
EP2519237A1 (en) 2012-11-07
RU2012132443A (ru) 2014-02-10
WO2011081221A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
MX2012007671A (es) Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea.
HRP20181785T1 (hr) Proces za pripremanje metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilkarbamata za uporabu kao farmaceutski aktivnog sastojka
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
MX2012000414A (es) Derivados piridin-4-ilo.
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
MX2007007272A (es) 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk.
MX2010001535A (es) Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa.
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
MX2011008389A (es) Sal de tipo tosilato de un derivado de 5-pirazolil-2-piridona, util en el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc).
MX2013000001A (es) Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral.
WO2009134866A3 (en) Cell membrane engineering
IL219861A0 (en) Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate and its purification for use as pharmaceutically active compound
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
JP2013515676A5 (es)
MX2014005075A (es) Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
MX2007006744A (es) Derivados de hidantoina utiles como inhibidores de metaloproteinasa.
WO2012020412A3 (en) Fibrin based scaffold, preparation and use thereof
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
EP2583969A4 (en) NEW RHODANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS WITH THE RHODANIN DERIVATIVES AS ACTIVE AGENTS
IL209270A (en) Compounds containing tricyclic nitrogen and their use as antibacterial
WO2011025167A3 (ko) 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용 가능한 염을 포함하는 암 예방 또는 치료용 약학 조성물
TW200800977A (en) A new salt

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SENJU PHARMACEUTICAL CO., LTD.

FG Grant or registration